GTR Test Accession:
Help
GTR000613342.1
Registered in GTR:
2024-07-22
View version history
GTR000613342.1,
registered in GTR:
2024-07-22
Last annual review date for the lab: 2024-07-22
LinkOut
At a Glance
Test purpose:
Help
Diagnosis;
Risk Assessment;
Screening
Conditions (1):
Help
Multiple endocrine neoplasia, type 1
Genes (2):
Help
CDKN1B (12p13.1);
MEN1 (11q13.1)
Methods (1):
Help
Molecular Genetics - Sequence analysis of the entire coding region: Next-Generation (NGS)/Massively parallel sequencing (MPS)
Target population: Help
Meet Ontario Health Hereditary Cancer Testing criteria
Clinical validity:
Help
Not provided
Clinical utility:
Help
Not provided
Ordering Information
Offered by:
Help
Test short name:
Help
MEN1
Manufacturer's name:
Help
SOPHiA
Specimen Source:
Help
- Cell culture
- Fibroblasts
- Peripheral (whole) blood
- Saliva
- Skin
Who can order: Help
- Genetic Counselor
- Health Care Provider
Test Order Code:
Help
MEN1
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order:
Help
Test development:
Help
Manufactured (research use only; not FDA-reviewed)
Informed consent required:
Help
Yes
Pre-test genetic counseling required:
Help
Yes
Post-test genetic counseling required:
Help
Yes
Recommended fields not provided:
Lab contact for this test,
Test strategy
Conditions
Help
Total conditions: 1
Condition/Phenotype | Identifier |
---|
Test Targets
Genes
Help
Total genes: 2
Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
---|
Methodology
Total methods: 1
Method Category
Help
Test method
Help
Instrument
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Illumina NextSeq 550
Clinical Information
Test purpose:
Help
Diagnosis;
Risk Assessment;
Screening
Target population:
Help
Meet Ontario Health Hereditary Cancer Testing criteria
Recommended fields not provided:
Clinical validity,
Clinical utility,
What is the protocol for interpreting a variation as a VUS?,
Is research allowed on the sample after clinical testing is complete?,
Sample negative report,
Sample positive report
Technical Information
Test Platform:
SOPHiA DDM CHCS_AA_v1
Test Comments:
Help
Sequence and copy number variant analysis
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
sensitivity: ~99%; specficity: 100%
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
European Molecular Genetics Quality Network, EMQN
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
European Molecular Genetics Quality Network, EMQN
Recommended fields not provided:
Test Confirmation,
Assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Not provided
Additional Information
Suggested reading:
Clinical resources:
Molecular resources:
Practice guidelines:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.